In a time of increasing cost pressures, limited resource capacity, and heightened demand for new treatments, Health Technology Assessments (HTAs) play a vital role in evaluating whether new
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh